Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How AI will transform mental health support for patients with breast cancer

2.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

3.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

4.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

5.

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot